Retrospective cohort study reports high survival rates following standard chemotherapy in classical Hodgkin lymphoma, highlighting favorable outcomes in regional clinical practice.
Key Points
To assess the clinical presentation, risk stratification, and survival outcomes among classical Hodgkin lymphoma patients treated at a regional tertiary cancer center.
Retrospective review of 55 patients treated between January 2011 and December 2019 at a tertiary cancer center in Southern India with a median follow-up of 29 months.
Evaluated baseline risk using the International Prognostic Score, histological subtypes, and administration of ABVD chemotherapy and radiotherapy.
Complete response was achieved in 61.1% of patients, with 88% receiving chemotherapy (primarily ABVD) and 13% receiving radiotherapy.
Disease-free survival was 87.6% at 2 years and 72.5% at 5 years.
Overall survival reached 95.4% at 2 years and 84.8% at 5 years across the cohort.